The Fly

Edwards Lifesciences price target lowered to $105 from $118 at RBC Capital

RBC Capital analyst Shagun Singh lowered the firm’s price target on Edwards Lifesciences to $105 from $118 and keeps an Outperform rating on the shares. Edwards is hosting an investor conference on Thursday, December 8, and plans to discuss its innovation strategy, and product pipeline, as well as provide a financial outlook for 2023. Singh expects focus on trends in U.S. TAVR volumes and expectations around staffing, U.S. Pascal ramp, and the impact of FX to the P&L, the analyst tells investors in a research note.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on EW:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More